TB
Therapeutic Areas
Scinai Immunotherapeutics Pipeline
| Drug | Indication | Phase |
|---|---|---|
| SCN-101 (COVID-19 hIVIG) | Severe COVID-19 | Phase 2/3 |
| BionicMimics™ Platform | Inflammatory/Autoimmune Diseases | Discovery |
Leadership Team at Scinai Immunotherapeutics
AR
Amir Reichman
Chief Executive Officer
JP
Joshua Phillipson
SVP, Business Development
BG
Boaz Gur-Lavie
Chief Financial Officer